Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), ADMA Biologics (ADMA) and Veracyte (VCYT)
Buy Rating Affirmed for Paragon 28 Amid Revenue Growth and Positive EBITDA Outlook
Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Paragon 28 (FNA)
Paragon 28 Analyst Ratings
Needham Maintains Buy on Paragon 28, Lowers Price Target to $11
Buy Rating Affirmed for Paragon 28 Amid Strong Financial Performance and Strategic Growth
CCORF Maintains Paragon 28(FNA.US) With Buy Rating, Maintains Target Price $17
J.P. Morgan Securities: Maintaining the Paragon 28 (FNA.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $23.00 to $20.00.
Paragon 28 Analyst Ratings
JMP Securities Maintains Market Outperform on Paragon 28, Lowers Price Target to $20
Paragon 28 (FNA) Gets a Buy From Piper Sandler
Needham: Maintains Paragon 28 (FNA.US) rating, adjusted from buy to buy rating, and adjusted target price from $17.00 to $14.00.
Paragon 28 Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Zentalis Pharmaceuticals (ZNTL) and Paragon 28 (FNA)
Paragon 28's Sustained Growth and Strategic Initiatives Bolster Buy Rating
Analysts Are Bullish on These Healthcare Stocks: Paragon 28 (FNA), Prothena (PRTA)
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Paragon 28 (FNA) and Intra-Cellular Therapies (ITCI)
Analysts Are Bullish on Top Healthcare Stocks: Paragon 28 (FNA), Caribou Biosciences (CRBU)
Maintaining a Buy: Paragon 28's Strong Q1 Performance and Optimistic Financial Outlook Despite CFO Transition
Paragon 28 Analyst Ratings